A study regarding the role of circulating CXCL9 and CXCL10 as potential markers for GO activity revealed that GC treatment and teleradiotherapy significantly decreased CXCL9 and CXCL10 serum concentrations compared with basal values in GO patients. This evidence concerns the gene CXCL9 and geroderma osteodysplastica.